Purchase 5F-ADB
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy 5F-ADB for sale
As a designer drug, 5F-ADB, also known as 5F-MDMB-PINACA, is a solid synthetic cannabis distributed online. This indazole-based chemical has been used as an active component in synthetic cannabis products. 5F-ADB is not a safe or legal drug, and its usage can have severe and even fatal consequences despite its widespread availability.
In this post, we will discuss the hazards of 5F-ADB and its potential consequences on the human body. The history of 5F-ADB, from its original discovery through its designation as a Schedule I restricted drug, will also be examined. Finally, we will address some commonly asked questions concerning 5F-ADB to offer a thorough knowledge of this hazardous drug.
What is 5F-ADB?
5F-ADB is a synthetic cannabinoid developed to imitate the effects of THC, the psychoactive component of cannabis. However, unlike THC, a naturally occurring drug, 5F-ADB is a laboratory-produced synthetic molecule. This implies that the potency, purity, and composition of 5F-ADB might vary significantly across batches, making it exceedingly difficult to manage its effects.
How Does 5F-ADB Work?
5F-ADB is a potent agonist of the CB1 receptor, the same receptor to which THC binds. When 5F-ADB binds to the CB1 receptor, many responses are triggered, including an increase in heart rate, a decrease in hunger, and a sensation of pleasure.
The Discovery of 5F-ADB
5F-ADB was found for the first time in November 2014 from post-mortem samples acquired from a person who died after consuming a product containing this chemical. Subsequent testing revealed the presence of 5F-ADB in 10 Japanese drug overdose deaths between September 2014 and December 2014.
The Classification of 5F-ADB
In December 2014, 5F-ADB was designated as a Schedule I restricted drug in the United States due to its hazardous effects. This categorization indicates that 5F-ADB has a significant potential for abuse, no acknowledged medicinal purpose, and an unacceptably low safety profile for usage under medical supervision.
The Effects of 5F-ADB
5F-ADB can have various effects on the human body, some of which are potentially lethal. Among the most typical effects of 5F-ADB are the following:
-An increase in heart rate
-A decrease in appetite
-A feeling of euphoria
-Dizziness
-Nausea
-Confusion
-Paranoia
5F-ADB can induce convulsions, respiratory depression, and even death in extreme situations. Because 5F-ADB is not a naturally occurring drug, it is hard to anticipate how a person will respond to it, making its usage exceedingly hazardous.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics